Protein glycation - Between tissue aging and protection

Exp Gerontol. 2015 Aug:68:71-5. doi: 10.1016/j.exger.2014.12.013. Epub 2014 Dec 20.

Abstract

Non-enzymatic formation of advanced glycation endproducts (AGEs) is associated with degenerative diseases. Chronic accumulation of AGEs with age in tissues especially in the extracellular matrix is well known and at least in part responsible for e.g., collagen crosslinking, tissue stiffening and thus induction of high blood pressure or diastolic heart failure. Binding of soluble AGEs to the receptor for AGEs, RAGE, induces an inflammatory response whereas the soluble form of RAGE (sRAGE) can inhibit inflammatory tissue injury like arteriosclerosis in mouse models. However, there are a number of indications that AGEs have protective effects as well. AGEs may inhibit lung tumor growth, glyoxal induced AGE modification of human heart muscle can reduce an ischemia reperfusion injury and AGEs from nutrition can reduce ROS induced cell damage.

Conclusions: In summary, this indicates that protein glycation behaves like a double-edged sword. It induces tissue aging and degenerative diseases on the one hand, on the other hand, may also have protective effects, indicating a hormetic response.

Keywords: Advanced glycation endproducts; Aging; Cardiovascular diseases; Glycation; Ischemia–reperfusion injury; Tumor formation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Aging / physiology*
  • Animals
  • Disease Models, Animal
  • Food
  • Glycation End Products, Advanced / metabolism*
  • Glycosylation
  • Humans
  • Lung Neoplasms / physiopathology
  • Lung Neoplasms / prevention & control
  • Mice
  • Middle Aged
  • Receptor for Advanced Glycation End Products / metabolism
  • Reperfusion Injury / physiopathology
  • Reperfusion Injury / prevention & control

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products